These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 28264697)

  • 1. Circulating gamma-glutamyl transferase and development of specific breast cancer subtypes: findings from the Apolipoprotein Mortality Risk (AMORIS) cohort.
    Shackshaft L; Van Hemelrijck M; Garmo H; Malmström H; Lambe M; Hammar N; Walldius G; Jungner I; Wulaningsih W
    Breast Cancer Res; 2017 Mar; 19(1):22. PubMed ID: 28264697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parity, hormones and breast cancer subtypes - results from a large nested case-control study in a national screening program.
    Ellingjord-Dale M; Vos L; Tretli S; Hofvind S; Dos-Santos-Silva I; Ursin G
    Breast Cancer Res; 2017 Jan; 19(1):10. PubMed ID: 28114999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breast Cancer Survival Analysis Based on Immunohistochemistry Subtypes (ER/PR/HER2): a Retrospective Cohort Study.
    Poorolajal J; Nafissi N; Akbari ME; Mahjub H; Esmailnasab N; Babaee E
    Arch Iran Med; 2016 Oct; 19(10):680-686. PubMed ID: 27743431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum enterolactone and postmenopausal breast cancer risk by estrogen, progesterone and herceptin 2 receptor status.
    Zaineddin AK; Vrieling A; Buck K; Becker S; Linseisen J; Flesch-Janys D; Kaaks R; Chang-Claude J
    Int J Cancer; 2012 Mar; 130(6):1401-10. PubMed ID: 21544804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of mortality of node-negative, ER/PR/HER2 breast cancer subtypes in T1, T2, and T3 tumors.
    Parise CA; Caggiano V
    Breast Cancer Res Treat; 2017 Oct; 165(3):743-750. PubMed ID: 28689363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dietary fiber intake and risk of postmenopausal breast cancer defined by estrogen and progesterone receptor status--a prospective cohort study among Swedish women.
    Suzuki R; Rylander-Rudqvist T; Ye W; Saji S; Adlercreutz H; Wolk A
    Int J Cancer; 2008 Jan; 122(2):403-12. PubMed ID: 17764112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathologic Characteristics of Oestrogen Receptor-Positive/Progesterone Receptor-Negative/Her2-Negative Breast Cancer According to a Novel Definition of Negative Progesterone Receptor Status: A Large Population-Based Study from China.
    Li AQ; Zhou SL; Li M; Xu Y; Shui RH; Yu BH; Yang WT
    PLoS One; 2015; 10(5):e0125067. PubMed ID: 25938238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated levels of circulating insulin-like growth factor-I, IGF-binding globulin-3 and testosterone predict hormone-dependent breast cancer in postmenopausal women: a case-control study.
    Kahán Z; Gardi J; Nyári T; Földesi I; Hajnal-Papp R; Ormándi K; Lázár G; Thurzó L; Schally AV
    Int J Oncol; 2006 Jul; 29(1):193-200. PubMed ID: 16773200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogen receptor, progesterone receptor, and HER2-neu expression in first primary breast cancers and risk of second primary contralateral breast cancer.
    Saltzman BS; Malone KE; McDougall JA; Daling JR; Li CI
    Breast Cancer Res Treat; 2012 Oct; 135(3):849-55. PubMed ID: 22903686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Night work and breast cancer risk defined by human epidermal growth factor receptor-2 (HER2) and hormone receptor status: A population-based case-control study in France.
    Cordina-Duverger E; Koudou Y; Truong T; Arveux P; Kerbrat P; Menegaux F; Guénel P
    Chronobiol Int; 2016; 33(6):783-7. PubMed ID: 27078711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.
    Parise CA; Bauer KR; Brown MM; Caggiano V
    Breast J; 2009; 15(6):593-602. PubMed ID: 19764994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct Effects of Body Mass Index and Waist/Hip Ratio on Risk of Breast Cancer by Joint Estrogen and Progestogen Receptor Status: Results from a Case-Control Study in Northern and Eastern China and Implications for Chemoprevention.
    Wang F; Liu L; Cui S; Tian F; Fan Z; Geng C; Cao X; Yang Z; Wang X; Liang H; Wang S; Jiang H; Duan X; Wang H; Li G; Wang Q; Zhang J; Jin F; Tang J; Li L; Zhu S; Zuo W; Ma Z; Zhou F; Yu L; Xiang Y; Li L; Shen S; Yu Z
    Oncologist; 2017 Dec; 22(12):1431-1443. PubMed ID: 28912152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors for hormone receptor-defined breast cancer in postmenopausal women.
    Rosenberg LU; Einarsdóttir K; Friman EI; Wedrén S; Dickman PW; Hall P; Magnusson C
    Cancer Epidemiol Biomarkers Prev; 2006 Dec; 15(12):2482-8. PubMed ID: 17164374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between body mass index and the expression of hormone receptors or human epidermal growth factor receptor 2 with respect to breast cancer survival.
    Jeon YW; Kang SH; Park MH; Lim W; Cho SH; Suh YJ
    BMC Cancer; 2015 Nov; 15():865. PubMed ID: 26546331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reproductive history and risk of three breast cancer subtypes defined by three biomarkers.
    Phipps AI; Buist DS; Malone KE; Barlow WE; Porter PL; Kerlikowske K; Li CI
    Cancer Causes Control; 2011 Mar; 22(3):399-405. PubMed ID: 21184265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hormone receptor and HER2 status in patients with breast cancer by races in southeastern Turkey.
    Kuzhan A; Adli M; Eryigit Alkis H; Caglayan D
    J BUON; 2013; 18(3):619-22. PubMed ID: 24065473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
    Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
    BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucose, lipids and gamma-glutamyl transferase measured before prostate cancer diagnosis and secondly diagnosed primary tumours: a prospective study in the Swedish AMORIS cohort.
    Bosco C; Garmo H; Hammar N; Walldius G; Jungner I; Malmström H; Holmberg L; Van Hemelrijck M
    BMC Cancer; 2018 Feb; 18(1):205. PubMed ID: 29463235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coordinated expression of ER, PR and HER2 define different prognostic subtypes among poorly differentiated breast carcinomas.
    Fernandes RC; Bevilacqua JL; Soares IC; Siqueira SA; Pires L; Hegg R; Carvalho FM
    Histopathology; 2009 Sep; 55(3):346-52. PubMed ID: 19723150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.